What we do Fredun Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in manufacturing and marketing of formulations, nutraceuticals, cosmeceuticals, pet healthcare, and mobility products, serving global markets. |
Founded in 1,987 |
Market share Leading manufacturer with strong presence in generics and niche segments across 52 countries. |
Problem solved Provides affordable and quality healthcare solutions in pharma formulations, pet care, and wellness products. |
Top clients or who we serve B2B and B2C customers including governments, hospitals, pharma distributors, and pet owners across India and global markets. |
Key management Dr. Daulat Medhora (Chairperson, PhD Chemistry), Mr. Fredun Medhora (Managing Director, MBA Strategic Marketing) |
Our journey and innovations Founded in 1987, expanded from single products to diversified pharma and wellness offerings, patent on bone graft, launched multiple new divisions including pet diagnostics. |
Where we operate India domestic market and exports to Africa, Southeast Asia, CIS, Latin America, and MENA regions. |
Top products or what we offer Generics under Fredun Gx, nutraceuticals, cosmeceuticals under Bird N Beauty, pet healthcare under Freossi, mobility aids and diagnostics. |
Top brands Fredun Gx (generics, #1 in segment expansion), Freossi (fastest growing pet care brand), Bird N Beauty (cosmeceuticals), Chuu Balm. |
Raw materials needed Active pharmaceutical ingredients, herbal extracts, nutritional supplements, packaging materials. |
Raw materials supplier Multiple suppliers across India and overseas specialized for pharma and nutraceutical raw materials. |
Recurring vs cyclical contribution Majority revenues recurring through long-term contracts and branded generics sales; export orders provide stable cash flows. |
Our industry position Well-positioned in Indian generics with growing niche presence in pet care and nutraceuticals, recognized by institutional and government contracts. |
Financial highlights FY25 revenue Rs. 456 crore, 31% YoY growth; PAT Rs. 20.8 crore with 4.6% margin; EBITDA Rs. 55.1 crore with 12.1% margin. |
Geographical revenue split 83% domestic and 17% export revenue as of FY25. |
Order book - |
Whats driving growth Product launches in generics and new divisions, capacity expansion, international registrations, government tenders, and pet care ecosystem development. |
Our future plans Expand non-pharma product share, launch new formulations, enhance export markets, scale pet diagnostics, and functional food manufacturing. |
Our green promise Energy conservation efforts, wastewater treatment, pollution control compliant with regulations, and waste recycling in manufacturing. |
Our people and values Employee-focused with strategic recruitment, training, including diversity and innovation-friendly culture. |
Key challenges ahead Regulatory compliance, competition in generics, price pressures, foreign exchange risks, and evolving market dynamics. |
Interesting facts Only Indian pharma to hold patent on bone graft material; launched India's first 24x7 pet diagnostic center; extensive global registrations. |
Risks and strategy Mitigates risks via diversification, robust internal controls, ongoing R&D, and increasing presence in high-margin niche healthcare segments. |
